At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 420 enrolled
Drug / intervention
insulin degludec/liraglutidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms
In Brief
A Phase 3 clinical trial evaluating insulin degludec/liraglutide for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 420 participants across 84 sites in 9 countries.
Detailed Summary
This trial is conducted in Europe, North America and the United States of America. The aim of this trial is to compare two different titration algorithms of insulin degludec/liraglutide.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesAustria, Bulgaria, Canada, Czechia, Hungary, Russia, Serbia, Slovakia, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartNov 2014
Primary CompletionDec 2015
TodayJul 2026
First PostedNov 21, 2014
Enrollment StartNov 21, 2014
Primary CompletionDec 23, 2015
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.6 years ago
Interventions
insulin degludec/liraglutidedrug
For subcutaneous (s.c., under the skin) injection, once daily. Subjects will be instructed to continue with the same dose of OADs (metformin alone or in combination with pioglitazone), as prior to the trial.